Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Return on Capital Employed (2021 - 2025)

Historic Return on Capital Employed for Vivos Therapeutics (VVOS) over the last 5 years, with Q3 2025 value amounting to 0.89%.

  • Vivos Therapeutics' Return on Capital Employed rose 3100.0% to 0.89% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.89%, marking a year-over-year increase of 3100.0%. This contributed to the annual value of 1.39% for FY2024, which is 21100.0% up from last year.
  • Per Vivos Therapeutics' latest filing, its Return on Capital Employed stood at 0.89% for Q3 2025, which was up 3100.0% from 1.16% recorded in Q2 2025.
  • In the past 5 years, Vivos Therapeutics' Return on Capital Employed registered a high of 0.54% during Q3 2021, and its lowest value of 5.35% during Q4 2023.
  • In the last 5 years, Vivos Therapeutics' Return on Capital Employed had a median value of 1.31% in 2022 and averaged 1.96%.
  • Its Return on Capital Employed has fluctuated over the past 5 years, first crashed by -26400bps in 2023, then surged by 42700bps in 2024.
  • Vivos Therapeutics' Return on Capital Employed (Quarter) stood at 0.68% in 2021, then plummeted by -297bps to 2.71% in 2022, then plummeted by -97bps to 5.35% in 2023, then skyrocketed by 80bps to 1.08% in 2024, then increased by 18bps to 0.89% in 2025.
  • Its last three reported values are 0.89% in Q3 2025, 1.16% for Q2 2025, and 1.32% during Q1 2025.